Congress instructed Foundation for the National Institutes of Health (FNIH) and the CDC Foundation to disclose certain information about donors in their annual reports. However, the FNIH and CDC Foundation have failed to abide by these instructions.
The Foundation for the National Institutes of Health (FNIH) and the CDC Foundation operate as intermediary organizations that facilitate partnerships between private research funders and researchers. Congress instructed these organizations to disclose certain information about donors in their annual reports. However, the FNIH and CDC Foundation have failed to abide by these instructions, raising transparency concerns.
The House Committee on Appropriations specified that these organizations must reveal the source and amount of every gift received. Also, the committee requires that the FNIH and CDC Foundation identify donors whose cash contributions involve restrictions, regardless of the donor’s anonymity, and restrictions placed on the use of the donations. Due to ethical issues that arose in recent years with both foundations, the committee released updated language in the spending agreement to emphasize the existing requirements, and warn the FNIH and CDC Foundation from further negligence.
Concerns were raised when the FNIH terminated a study examining the long-term effects of alcohol consumption. The alcohol industry donated nearly $100 million toward the research, but the project was shut down when investigators discovered that NIH workers inappropriately contacted industry figures—Congress strictly prohibits any contact between the researchers and their private donors.
Other cases that raised ethical concerns with FNIH involved concussion research and research into non-opioid alternatives for pain treatments. To address these concerns, the FNIH either rearranged partnerships or abandoned plans for new ones.
Attention was also drawn to another example of violations by CrossFit, Inc, which observed the disclosures of the FNIH and CDC Foundation and uncovered that both organizations failed to properly document the sources and amounts of donations they received. The chain of gyms and branded fitness regimen has been a major opposing force against the involvement of “Big Soda” in biomedical research.
Russ Greene, director of government relations and research, CrossFit, said in a statement, “We looked over the CDC Foundation’s and FNIH’s disclosures and found they weren’t even close to following the law. Annually reporting the sources, amount and restrictions of each grant they receive—transparency—is the first step in making sure there’s no undue influence on government science and policy.”
CrossFit staff notified a House committee about the FNIH and CDC Foundation’s inability to follow transparency laws, which prompted the House to deliver a message acknowledging the unethical practices of both organizations.
Potential Spillover Effects on Traditional Medicare When Physicians Bear Medicare Advantage Risk
February 26th 2025Medicare beneficiaries treated by physicians with high levels of Medicare Advantage risk exposure had higher care quality and efficiency outcomes compared with those treated by other physicians.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
A Glimpse Into the Future of Eye Care at SECO 2025
February 25th 2025Attendees can expect insights on advancements in glaucoma care, myopia management, dry eye treatments, emerging technologies, ocular disease myths, oral medications, the impact of obesity on ocular health, and more at the Southeastern Congress of Optometry (SECO) 2025.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen